Coeptis Therapeutics, Inc. (COEP) |
|
1.48 0.11 (8.03%)
|
03-24 16:00 |
|
Open: |
1.4 |
Pre. Close: |
1.37 |
|
High:
|
1.55 |
Low:
|
1.37 |
|
Volume:
|
101,994 |
Market Cap:
|
29(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:24:59 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 1.84 One year: 2.12 |
| Support: |
Support1: 1.19 Support2: 0.99 |
| Resistance: |
Resistance1: 1.57 Resistance2: 1.82 |
| Pivot: |
1.41  |
| Moving Average: |
MA(5): 1.41 MA(20): 1.48
MA(100): 1.84 MA(250): 6.78 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 39.4 %D(3): 35.9 |
| RSI: |
RSI(14): 50.6 |
| 52-week: |
High: 21.42 Low: 1.02 |
| Average Vol(K): |
3-Month: 109 (K) 10-Days: 74 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ COEP ] has closed below upper band by 34.1%. Bollinger Bands are 81.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 51 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.55 - 1.56 |
1.56 - 1.56 |
|
Low:
|
1.36 - 1.36 |
1.36 - 1.37 |
|
Close:
|
1.47 - 1.48 |
1.48 - 1.49 |
|
Company Description |
|
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania. |
Headline News |
Tue, 21 Mar 2023
Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted ... - PR Newswire
Tue, 07 Feb 2023
Coeptis Therapeutics and ShareIntel Enter Shareholder Service ... - PR Newswire
Tue, 31 Jan 2023
Coeptis Therapeutics Enters into Sponsored Research Agreement ... - PR Newswire
Tue, 22 Nov 2022
Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR ... - PR Newswire
Tue, 15 Nov 2022
Coeptis Therapeutics Holdings to Ring the Nasdaq Stock Market Opening Bell - Yahoo Finance
Wed, 02 Nov 2022
COEP Stock Forecast, Price & News (Coeptis Therapeutics) - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: PNK |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
5 (M) |
|
% Held by Insiders
|
1.114e+007 (%) |
|
% Held by Institutions
|
54.4 (%) |
|
Shares Short
|
48 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-3.282e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-224.5 |
|
Return on Equity (ttm)
|
-1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-1.8 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-3 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-4.81 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
150750 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
